Compare Booz Allen Hamilton Holding Corporation (BAH) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Biogen Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.51 (market cap $9.45B), while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 3.2× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BAH | BIIB | |
|---|---|---|
Market Cap | $9.45B | $30.13B |
Sector | Industrials | Health |
52-Week High | $111.63 | $216.63 |
52-Week Low | $59.71 | $128.93 |
Enterprise Value | $13.07B | $37.20B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $78.4, up 0.64% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 68.11% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights its focus on AI and cybersecurity, with a consensus analyst price target of $84.67 suggesting upside potential. Cash flow from operations improved to $1.01 billion in 2025.
The outlook is supported by national security demand and margin expansion, but risks include civil revenue weakness and high leverage. Valuation appears reasonable with a P/E of 12.33. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock offers a dividend yield from recent payouts.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
